Media - Our stories

Explore our recent stories to see what drives us

04 September 2025

Grünenthal PRO and SHL Medical partner to boost speed-to-market for Molly® autoinjectors final assembly

Biopharma autoinjector capabilities expansion
Grünenthal PRO is expanding its biopharma autoinjector capabilities through a strategic alliance with SHL Medical. A new pre-validated assembly line at our Origgio site will help pharmaceutical and biotech partners move faster and smarter.

Speed-to-market is a decisive advantage in today’s biopharma landscape, and Grünenthal PRO is stepping up to deliver it.

Grünenthal PRO, our CDMO division and a world-leading provider of autoinjector final assembly services, is expanding its capabilities through a new strategic alliance with SHL Medical, a global leader in advanced drug delivery systems. Together, we are combining SHL’s market leading device expertise with Grünenthal’s proven track record in high-quality, large-scale biopharma packaging.

By the end of 2026, our Origgio site in Italy will feature a new pre-validated final assembly line for Molly® autoinjectors, including both 1mL and 2.25mL formats. This investment builds on more than a decade of Grünenthal’s experience in SHL autoinjector final assembly and will enable faster timelines and simplified validation for pharmaceutical and biotech partners.

Victor Barbosa, Head of Global Operations and member of the Executive Board Team

“With our deep expertise in autoinjector final assembly and the new high-speed line launching in 2026, Grünenthal is uniquely positioned to deliver agile, large-scale solutions.”

Victor Barbosa,

Executive Vice President of Global Operations at Grünenthal

This collaboration reinforces Grünenthal’s role as a trusted CDMO partner for injectable therapies worldwide, offering scalable, high-quality solutions that help bring therapies to patients more swiftly.

 

Read the full press release (PDF).

Discover how our new assembly line can support your next launch. Reach out to Grünenthal PRO.

Share this story: